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INTRODUCTION AND 
BACKGROUND
PCOS is the most common endocrine disorder 
among women in the reproductive age with a 
prevalence of 10%. Women with PCOS are a 
complex heterogenous group.
 ■ The syndrome is defined by at least 2 of the 3 
following criteria (Rotterdam criteria 2003)
 ❏  Oligo- or amenorrhea
 ❏  Clinical signs of hyperandrogenism or 
biochemical hyperandrogenemia
 ❏  Sonographic evidence of at least one 
polycystic ovary
 ■ The syndrome has strong association to
 ❏  Obesity/overweight 
 ❏  Android fat distribution
 ❏  Infertility
 ❏  Insulin resistance (IR) (independent of 
bodyweight)
 ❏  Impaired glucose tolerance
 ❏  Dyslipidemia
 ■ IR and hyperandrogenism are associated with 
alterations in the hemostatic and fibrinolytic 
system leading to endothelial dysfunction and 
vascular chronic  low-grade inflammation
 ■ Reports on hemostasis in PCOS are conflicting
 ■ There is a need for large longterm prospective 
cohort studies in a well-defined PCOS 
population investigating coagulation and 
fibrinolysis pathways and cardiovascular 
morbidity.
HYPOTHESIS
 ■ Women with PCOS are characterized  by 4 main 
phenotypes and each phenotype has different 
risk profile with regard to diabetes, thrombosis 
and CVD ( Figure 1). 
 ■ The prognostic CVD risk in women with 
PCOS can be predicted based upon well 
validated molecular biomarkers (inflammation, 
metabolism, thrombosis, endogenous sex 
steroids) combined with a precise clinical 
evaluation of phenotype including distribution 
of body fat.  
 ■ There is correlation between dysmetabolic 
biomarkers and visceral obesity independent of 
BMI (body mass index).
Figure 1.
4 phenotypes of PCOS
OBJECTIVES
1. Based on the 4 phenotypes of PCOS : ± IR, ± 
obesity: 
•  define clusters of  biomarkers characterizing   
  the 4 phenotypes. 
•  assessment of prevalence of abdomial    
  obesity, metsbolic syndrome (MS)  and    
  hemostatic derrangements.
2. To optimize the clinical risk estimation  for  
diabetes and CVD including endothelial 
dysfunction,  vascular low–grade inflammation, 
and  thrombosis,  based on a simple clinical and 
paraclin ical  algorithm. 
3. Assessment of correlation between risk 
biomarkers and the individuel elements of the 
definiton of PCOS.  
4. To establish a PCOS database and bio bank 
based on a large well-defined and well-
characterized  population  (Figure 2).
STUDY DESIGN
Multi center cross-sectional clinical study
METHODS
 ■ Huge dataset and bio bank will be 
established with blood  and urine samples 
from  premenopausal 18-40 year old women 
with PCOS. Patients will be recruited from 4 
Copenhagen University Hospitals (Figure 2). 
Controls are required in the two of the three 
PICOLO projects, project 2 and 3.
 ■ The patients will be screened for metabolic and 
haemostatic derailments. DEXA scan and Oral 
glucose tolerance test (OGTT) will be performed 
(Figure  2+ Table 1).
RESULTS
Data are being compiled  from  April  2010 - 
December 2011 and results will be published from 
2012. 
CONCLUSION/PERSPECTIVES
 ■ Developement  of precise clinical and 
paraclinical algorithm will enable better 
diagnostic, counseling and appropriate 
treatment  of the women with PCOS.
 ■ Haematological parameters could potentially be 
used as indicators of risk of atherosclerotic and 
thrombotic disease in women with PCOS.
Table 1. 
Variables assessed at baseline evaluation
Categories Variables
Anthropometric variables waist-hip ratio, femoral circumference, height 
and weight, blood pressure, Ferriman-Gallwey 
score, acne score
Gynaecological endocrinology LH, FSH, progesterone*, estradiol, prolactin, 
TSH, 
Androgens total testosterone, free testosterone, SHBG, 
DHEAS 
Glucose metabolism glucose, c-peptide, insulin, OGTT
Lipids total cholesterol, LDL- cholesterol, HDL- chole-
sterol, triglycerides
Inflammation C-reactive protein
Liver and kidney ALAT, sodium, potassium, creatinine
Urine urine albumin, urine albumin/creatinine ratio
Bio bank Biomarkers for Chronic Low-grade vascular In-
flammation, Endothelial dysfunction, Haemo-
stasis/Thrombosis/CVD, placental function
* Only for women with regular menstrual cycle.
Figure 2.
Overview of the PICOLO project (Polycystic ovary syndrome: In-
fertility and co-morbidity including Cardiovascular and Obstetric 
risk assessment and Long-term Outcome)
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